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daily living (T-IADL) in carers of patients with Alzheimer’s disease (AD). Methods: 
GERAS is a prospective, non-interventional cohort study in AD patients and caregiv-
ers. The Zarit Burden Inventory (ZBI) and the EQ-5D were used to measure burden 
and HRQoL respectively. Spearman correlations were computed between EQ-5D, ZBI 
and T-IADL at baseline, 18-months and for change over 18-months. T-IADL and ZBI 
change scores were summarised by EQ-5D domain change category (better/stable/
worse). Results: 1495 caregivers were available at baseline [67 years (SD 12) and 
64% female]. According to baseline patient severity, caregivers’ EQ-5D health state 
values were 0.86, 0.85 and 0.82 and ZBI total scores were 25, 29 and 34 in mild, moder-
ate and moderately severe/severe AD respectively. T-IADL increased from a mean of 
79 hours (SD 89; median 60 hours) at baseline by a mean of 17 hours (SD 105; median 
10 hours) over 18-months, and showed a stronger correlation with ZBI than with 
EQ-5D, although correlations were low for both (e.g. change scores 0.118 ZBI; 0.020 
EQ-5D). Worsening within EQ-5D domains (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) was associated with the greatest increase in 
burden scores, although the majority of caregivers (68-90%) remained stable within 
each EQ-5D domain. Relative to these stable caregivers, larger increases in T-IADL 
over 18–months were associated with better ratings in mobility and usual activities 
but worsening in pain/discomfort. Larger increases in T-IADL were associated with 
both better and worse ratings in anxiety/depression [23.5 hours better (11%); 12.2 
hours stable (68%); 24.8 hours worse (16%)]. ConClusions: EQ-5D health state 
values had low sensitivity to changes in caregiver time over an 18-month period. 
ZBI may better reflect the impact of caring for AD patients.
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objeCtives: This systematic literature review (SLR) aimed to identify health state 
utility values among migraine patients. Methods: A SLR was conducted in bio-
medical databases and Health Technology Assessment (HTA) websites from 2000-
2014. Search terms included different combinations of migraine along with utility 
or quality-of-life measures. References of identified SLR/meta-analyses were inves-
tigated to identify additional studies. Each study was reviewed by two independent 
reviewers; disagreements were resolved by a third reviewer. Results: The search 
yielded 29 publications (including a submission to the National Institute for Health 
and Care Excellence) from which 23 studies were extracted. The studies were mainly 
conducted in US (n= 6), Canada (n= 5), or UK (n= 3). Sample sizes varied from 14 to 
> 8000. Age (mean: 21-47.5 years) was reported in 16 studies while disease duration 
(mean: 2.3-24 years) only in four. Proportion of females ranged between 70-80%. 
Pain and psychiatric disorders were the most common comorbidities. Migraine 
was primarily defined using the International Headache Society’s International 
Classification of Headache Disorders criteria (n= 10). Most studies used validated 
utility instruments: EQ-5D (n= 12), Health Utility Index-Mark 3 (n= 7) or SF-36 (n= 1) 
to assess utility values. Three studies used the Quality of Well Being scale, and two 
used custom questionnaires, using Time Trade Off or Standard Gamble techniques. 
Utilities values were reported using the following categories: by migraine pain sever-
ity (pain-free [0.87-0.96], mild [0.66-0.84], moderate [0.51-0.77] or severe [0.39-0.54]), 
by number of migraine days/month (or percentage reduction in migraine frequency: 
< 50% to ≥ 75% associated with a utility increase: 0.001 to 0.010), or by migraine type 
(chronic [0.43-0.89]/episodic [0.62-0.91]). ConClusions: This SLR confirmed that 
increased migraine frequency and pain severity were associated with lower utility 
values among migraineures. A wide range of utility values were reported; potential 
differences across reported estimates are likely due to different populations or dif-
ferent methodologies implemented to derive estimates.
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objeCtives: Treatment Satisfaction Questionnaire for Medication (TSQM) (score 
range 0-100) has been shown to be a reliable and valid instrument to measure 
patients’ satisfaction with their treatment for multiple sclerosis (MS). The 14-item 
TSQM Version1.4 provides scores across four domains: effectiveness, convenience, 
global satisfaction, and side effects. The abbreviated 9-item TQSM-9 excludes the 
side effects domain. Positive changes in score indicate improvement. We conducted 
a systematic review of clinical studies that reported MS patient satisfaction with 
their disease-modifying therapies (DMTs) using TSQM. Methods: We systemati-
cally searched EMBASE, MEDLINE, BIOSIS Previews and Medmeme with pre-specified 
search terms from 2004 onwards for manuscripts and conference proceedings of 
prospective MS studies. The outcomes of interest included study type, change from 
baseline (CFB) in TSQM scores by DMT group, and differences in CFB in TSQM across 
treatment groups. Results: Six studies met all study criteria (3 single-arm observa-
tional or surveillance studies and 3 randomized studies). The DMTs studied included 
interferon beta-1b, glatiramer acetate, fingolimod, teriflunomide, and natalizumab. 
Two studies used TSQM Version1.4, while four used TSQM-9. Study length ranged from 
12 weeks to 3 years. CFB at 6 months was the most commonly reported outcome. The 
CFB at 6 months on the effectiveness subscale ranged from 1.8 to 26.9, convenience 
subscale from 3.6 to 41.2, and global satisfaction subscale from 2.9 to 20.4. The CFB 
at 6 months was generally higher for natalizumab and fingolimod compared with 
injectable platform DMTs, although this finding may be confounded by the differ-
ences in study design and patient characteristics. ConClusions: Several MS studies 
have used the TSQM to measure patient satisfaction with DMTs. Comparisons across 
identified studies is challenging, as there is substantial heterogeneity with regards to 
version of TSQM used, study type and length, and type of analyses reported.
main contributor to societal costs. Although time on basic and instrumental ADLs 
differed across countries, some of this may be explained by use of community 
care services and institutionalization. Other resources had different patterns of 
use across countries, reflecting country-specific health and social care systems.
NeuroLogicaL DiSorDerS – Patient-reported outcomes & Patient Preference 
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objeCtives: To perform a systematic literature review of adherence to inhaled 
antibiotics for the treatment of chronic Pseudomonas Aeruginosa (PA) infection in 
patients with cystic fibrosis (CF). Methods: A systematic literature search of English-
language articles was conducted in April 2014 using Medline and Embase. No publica-
tion date limit was applied. The literature screening was conducted by 2 independent 
reviewers. All of the included studies were assessed for quality. Results: The search 
yielded 192 publications, of which 9 met the inclusion criteria and underwent data 
extraction. Six studies focused on inhaled tobramycin, 1 on inhaled colistimethate, 1 
on inhaled levofloxacin, and 1 on inhaled aztreonam lysine. Medication adherence to 
inhaled antibiotics was analyzed by pharmacy refill history, daily phone diary, parent 
and child self-reports, vials counting, or electronic monitoring. Proportion of adherent 
patients (≥ 75%/80% of required doses taken) in randomized clinical trials (n= 3) ranged 
from 86% to 97%; adherence rates in prospective cohort studies (n= 2) ranged between 
36% and 92%, and in retrospective studies (n= 4) ranged between 60% and 70%. The 
adherence to inhaled antibiotics in CF was found to be associated with the complex-
ity of treatment, time of drug administration, age of patients, treatment burden (i.e., 
adverse events, taste), and patient satisfaction. ConClusions: Adherence varied 
depending on the type of study, type of treatment, and method of measurement. In 
real-world trials, poor adherence to inhaled antibiotics was found in patients with CF. 
Regular routine adherence monitoring during CF care, discussion about sub-optimal 
adherence and treatment reinforcement on the basis of treatment burden, clinical 
status, and adverse events may help to better understand the predictors and the 
long-term consequences of non-adherence to inhaled antibiotics for the treatment 
of chronic PA infection in CF.
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objeCtives: Pharmacological management of relapsing-remitting multiple sclerosis 
(RRMS) includes the use of oral, injectable, or infusible Disease Modifying Therapies 
(DMTs). Achieving therapeutic goals in MS requires strict adherence to medication 
administration schedule. To assess compliance and discontinuation rates with DMTs 
in Canadian patients with RRMS. Methods: This non-interventional, retrospec-
tive analysis was based on private claims patient cohorts accessed through IMS Rx 
Dynamics®. Patients had at least one prescription filled for each DMT (oral: fingoli-
mod, dimethyl fumarate (DMF), teriflunomide; injectable (BRACE): interferon beta-1a, 
interferon beta-1b, glatiramer acetate; infusible: natalizumab). Patients were compli-
ant if the medication possession ratio (MPR) was ≥ 80%. Discontinuation rates were 
calculated based on patients who stopped therapy or who were switched to another 
DMT. Compliance and discontinuation rates were collected at 6-month intervals with 
compliance cohorts from August 2011 to December 2014 (rolling 36 months total) and 
discontinuation cohorts from September 2011 to January 2015. Results: Compliance 
data was collected for 10315 patients (fingolimod, n= 1524; DMF, n= 1828; terifluno-
mide, n= 456; natalizumab, n= 604; BRACE, n= 5903). Compliance rate across Canada 
was higher for fingolimod (78%) compared to other DMTs, including natalizumab 
(72%), DMF (70%), and BRACE (56%). In Quebec, fingolimod had a compliance rate of 
80%, higher than DMF (68%) and BRACE (65%). Patients on fingolimod had the low-
est discontinuation rate across Canada (22%), compared to natalizumab (30%) and 
BRACE (47%). In Quebec, DMF had a higher discontinuation rate (29%) than other orals 
(fingolimod, 20%; teriflunomide, 23%) and natalizumab (25%). ConClusions: In a 
Canadian real-world setting, the compliance rate with fingolimod was higher than 
for other DMTs while the discontinuation rate with fingolimod was lower compared 
to other DMTs. These findings may facilitate MS management strategies which may 
lead to improved clinical and economic outcomes. Findings based in part on data 
licensed from IMS Health Canada Inc. All Rights Reserved.
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objeCtives: To describe the relationship between caregiver health-related quality 
of life (HRQoL), caregiver burden and caregiver time for instrumental activities of 
